Welcome to Jaime Mendoza’s profile!

Jaime Mendoza is a healthcare professional with a diverse nursing and psychiatric mental health background. She graduated from Southern Illinois University Edwardsville in 2012, obtaining a Family Nurse Practitioner (FNP) degree. In 2017, she furthered her education by completing a Psychiatric Mental Health Nurse Practitioner (PMHNP) program at Northern Kentucky University.

Jaime has been associated with Southern Illinois Associates since May 2013, where she has been actively contributing her expertise. From May 2013 to September 2019, she was a Nurse Practitioner at HSHS Holy Family Hospital. Before that, from November 2012 to March 2013, she worked as a Staff Registered Nurse at SMGS-Mt. Vernon Family Health Center in Mt. Vernon, Illinois.

Jaime has participated in research and publication activities during her career. One of her notable research endeavors includes being the  Investigator for a Postmarketing Observational Study on the safety evaluation of ADASUVE® (STACCATO® Loxapine for Inhalation) in patients with agitation associated with schizophrenia or bipolar I disorder. This study took place from June 2019 to January 2019 and was sponsored by H. Lundbeck A/S (Lundbeck).

Additionally, Jaime has been involved in a non-interventional, multi-national, prospective cohort study to assess the real-life effectiveness of vortioxetine in patients with major depressive disorder.

Regarding her clinical expertise, Jaime is trained in Transcranial Magnetic Stimulation (TMS), Esketamine treatment, and Vagal Nerve Stimulation (VNS). She possesses extensive experience working with the group home population and geriatric patients.

Jaime Mendoza is committed to providing quality healthcare and utilizing her skills and knowledge to assist individuals with psychiatric and mental health needs.

Transcranial Magnetic Stimulation (TMS) and Esketamine are treatments used for treatment-resistant depression. Here’s a brief explanation of each:

Transcranial Magnetic Stimulation (TMS): TMS is a non-invasive procedure that uses magnetic fields to stimulate specific brain areas. It is typically used when other depression treatments have been ineffective. During a TMS session, an electromagnetic coil is placed against the scalp, delivering magnetic pulses to the targeted brain regions. These pulses help to regulate the brain’s activity and can alleviate symptoms of depression. TMS is usually administered over several weeks, lasting about 20 to 40 minutes. It is a safe and well-tolerated treatment option for individuals with treatment-resistant depression.

Esketamine: Esketamine is a nasal spray medication that is used in conjunction with an oral antidepressant for the treatment of treatment-resistant depression. It belongs to a class of drugs known as NMDA receptor antagonists and works by targeting certain neurotransmitters in the brain. Esketamine acts relatively quickly compared to traditional antidepressants and can provide rapid relief for individuals experiencing depressive symptoms. Due to its potential side effects and the risk of abuse or misuse, ketamine is only available through a restricted distribution program and is administered under close medical supervision.

TMS and ketamine are considered alternative treatment options for individuals who have not responded well to other depression treatments. They should be administered and monitored by qualified healthcare professionals specializing in treating psychiatric conditions.